GlassScriptPhysician profile
David S Kleinman
NPI 1639123755
$2,277.60
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $970 · 2020: $413 · 2021: $894.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $553.81 | 2019-2021 | |
| Novo Nordisk INC | $551.33 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $300.23 | 2019-2021 | |
| Lilly USA, LLC | $211.83 | 2019-2021 | |
| Abbott Laboratories | $157.13 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $109.92 | 2019 | |
| Abbvie INC. | $91.31 | 2019 | |
| Xeris Pharmaceuticals, INC. | $59.32 | 2020-2021 | |
| Dexcom, INC. | $44.28 | 2021 | |
| Shire North American Group INC | $41.07 | 2019 | |
| Pfizer INC. | $39.78 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.23 | 2021 | |
| Rhodes Pharmaceuticals L.P. | $20.39 | 2019 | |
| Boston Scientific Corporation | $19.19 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.60 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $13.53 | 2021 | |
| Sun Pharmaceutical Industries INC. | $11.69 | 2019 | |
| Recordati_rare_diseases_inc. | $10.96 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kleinman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.